Nitroxyl (HNO) has recently emerged as a prospective pharmacological agent. Studies of the chemistry of HNO have led to an understanding that HNO is vastly different from nitric oxide (NO). HNO displays unique cardiovascular properties and has been shown to have positive effects in failing hearts without changing heart rate, and also has been shown to have beneficial effects in ischemia reperfusion injury. In addition to the observed cardiovascular effects, HNO has shown initial promise in the realm of cancer therapy. HNO has been demonstrated to inhibit a key glycolytic enzyme. Due to the Warburg effect, inhibiting glycolysis is an attractive target for inhibiting tumor proliferation. HNO has recently been shown to inhibit tumor proliferation in mouse xenografts. Additionally, HNO inhibits tumor angiogenesis and induces cancer cell apoptosis.

The National Cancer Institute's Cancer and Inflammation Program discovered HNO releasing compounds and methods of treating various diseases with such compounds.

NIH Ref. No.:

E-019-2010

Advantages:

Alleviated toxicity associated with chronic NSAID use
Controlled release of HNO

Applications:

Potential treatment for cardiovascular disease, ischemia, and cancer.
Tool to probe the role of HNO in normal physiology and disease states.

Development Status:

Discovery (Lead Identification)

Updated On:

Mar 29, 2018

Provider Classifications:

Patent Application:

61/315,604

Patent Authority:

U.S. Provisional

Inventor IC:

NCI

Inventor Lab URL:

http://irp.nih.gov/pi/david-wink

https://ccr2.cancer.gov/resources/cbl/Scientists/keefer.aspx

LPM FIrst Name:

John

LPM Last Name:

Hewes

LPM Phone:

240-276-5515

LPM Email:

John.Hewes@nih.gov

LPM Organization:

NCI - National Cancer Institute

DTDT Classification:

Therapeutics

DTDT Description:

Therapeutics

Pat Filing Date:

2010-03-19

Publication Link:

https://www.ncbi.nlm.nih.gov/pubmed/19426703

https://www.ncbi.nlm.nih.gov/pubmed/16101424

Publication Caption:

PMID 19426703

PMID 16101424

Publication Title:

Switzer C et al. The emergence on nitroxyl (HNO) as a pharmacological agent.

Keefer, LK. Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities.

Collaboration Sought:

Yes

Institute or Center:

Collaboration Opportunity:

Licensing only

E Number Only:

E-019-2010

Inventor First Name:

David

Larry

Inventor Last Name:

Wink

Keefer

Nitroxyl (HNO) Releasing Therapeutics

More From BioPortfolio on "Nitroxyl (HNO) Releasing Therapeutics"